ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1907

Twenty-Year Trends in the U.S. Burden of Gout: A State-Level Analysis of Disability and Prevalence from 2001 to 2021

Shiza sarfraz, Hassam Ali and debargha basuli, East Carolina University Brody School of Medicine, Greenville, NC

Meeting: ACR Convergence 2025

Keywords: Disability, Disparities, Epidemiology, gout

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, October 28, 2025

Title: (1877–1913) Epidemiology & Public Health Poster III

Session Type: Poster Session C

Session Time: 10:30AM-12:30PM

Background/Purpose: Gout is the most common inflammatory arthritis and an important driver of chronic disability. However, long-term trends in gout burden across U.S. states are not well-characterized. Using nationally representative data, we aimed to quantify changes in age-standardized gout-related disability-adjusted life years (DALYs), years lived with disability (YLDs), and prevalence rates between 2001 and 2021, with a focus on regional disparities.

Methods: We extracted age-standardized DALY, YLD, and prevalence rates for gout from the Global Burden of Disease 2021 dataset for adult patients. Annual rates per 100,000 population were obtained for all 50 U.S. states and the national average from 2001 to 2021. We calculated national trends with 95% confidence intervals (CIs) and computed percent change in burden over time for each state. The ten states with the highest burden in 2021 were identified.

Results: Between 2001 and 2021, the national average DALY rate for gout increased from 53.1 (95% CI: 51.4–54.8) to 102.9 (95% CI: 99.4–106.4) per 100,000—a 93.7% increase. The YLD rate mirrored this trend, rising from 53.1 (95% CI: 51.4–54.8) to 102.9 (95% CI: 99.4–106.4). The prevalence rate more than doubled, from 1,677.2 to 3,408.9 per 100,000 (+103.2%). In 2021, the states with the highest DALY and YLD rates included Hawaii (147.7, +93.3%), South Carolina (124.7, +107.4%), Alabama (123.0, +114.0%), and Louisiana (120.4, +99.6%). Prevalence rates followed a similar pattern, with Hawaii (4,902.4, +98.6%), South Carolina (4,185.0, +114.0%), and Alabama (4,104.9, +118.2%) ranking among the highest. All ten highest-burden states demonstrated steep upward trajectories over the two-decade period (Figure 1). Regional clustering was evident, with the Southeast disproportionately represented (Figure 2).

Conclusion: The prevalence and disability burden of gout in the United States have more than doubled over the past 20 years. DALY and YLD rates show that the impact of gout extends beyond symptoms, contributing significantly to long-term health loss. Southern and Western states carry the highest burden, emphasizing the need for targeted public health strategies.

Supporting image 1Trends in gout burden among the top 10 most affected U.S. states, 2001–2021.

Supporting image 2Geographic variation in gout burden across U.S. states in 2021.


Disclosures: S. sarfraz: None; H. Ali: None; d. basuli: None.

To cite this abstract in AMA style:

sarfraz S, Ali H, basuli d. Twenty-Year Trends in the U.S. Burden of Gout: A State-Level Analysis of Disability and Prevalence from 2001 to 2021 [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/twenty-year-trends-in-the-u-s-burden-of-gout-a-state-level-analysis-of-disability-and-prevalence-from-2001-to-2021/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/twenty-year-trends-in-the-u-s-burden-of-gout-a-state-level-analysis-of-disability-and-prevalence-from-2001-to-2021/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology